<?xml version="1.0" encoding="UTF-8"?>
<p id="p0145">
 <italic>ChAdOx1</italic> from the University of Oxford is an adenovirus vector-based vaccine and plans to run parallel phase I-II trials on 510 volunteers for safety and efficacy. The Oxford group has experience with candidate vaccine for MERS-CoV (ChAdOx-MERS) and has undergone a successful phase I trial for safety. The group is pushing ahead with an aggressive clinical plan and is talking of an emergency-use vaccine ready in September 2020.
 <xref rid="bib77" ref-type="bibr">77</xref>, 
 <xref rid="bib78" ref-type="bibr">78</xref>, 
 <xref rid="bib79" ref-type="bibr">79</xref>
</p>
